Open AccessPB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT‐ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL‐WORLD SINGLE CENTER EXPERIENCE
Author(s) -
Elsabah H.,
Kassem N.,
Gulied A.,
Taha R.,
Elomri H.,
Cherif H.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850820.70181.23
Subject(s) - medicine , lenalidomide , daratumumab , multiple myeloma , bortezomib , single center , gastroenterology , dexamethasone , oncology , creatinine , surgery